title: Successful treatment of minimal residual disease-positive Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib followed by reduced-intensity unrelated cord blood transplantation after allogeneic peripheral blood stem cell transplantation.
abstract: We describe a 35-year-old woman with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who received allogeneic sibling donor peripheral blood stem cell transplantation (PBSCT) and entered a second complete remission. Upon detection of BCR-ABL transcripts after PBSCT, the patient received imatinib, leading to molecular remission. Following the failure of donor leukocyte infusions, she underwent reduced-intensity unrelated cord blood transplantation (RI-UCBT), and has continued durable molecular remission for more than 30 months without substantial graft-versus-host disease. Because of a lack of adverse effects of imatinib on transplantation outcome, a treatment strategy consisting of molecular monitoring-guided initiation of imatinib followed by RI-UCBT may be promising in the management of Ph+ ALL after allogeneic SCT.
authors.affiliation: Department of Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine, Kanazawa, Ishikawa, Japan. takami@med3.m.kanazawa-u.ac.jp
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Takami
authors.forename: Shigeru
authors.initials: S
authors.lastname: Shimadoi
authors.forename: Chiharu
authors.initials: C
authors.lastname: Sugimori
authors.forename: Kenichi
authors.initials: K
authors.lastname: Takemoto
authors.forename: Masami
authors.initials: M
authors.lastname: Shibayama
authors.forename: Tomotaka
authors.initials: T
authors.lastname: Yoshida
authors.forename: Tohru
authors.initials: T
authors.lastname: Murayama
authors.forename: Kenichi
authors.initials: K
authors.lastname: Nagai
authors.forename: Koichi
authors.initials: K
authors.lastname: Miyamura
authors.forename: Hidesaku
authors.initials: H
authors.lastname: Asakura
authors.forename: Shinji
authors.initials: S
authors.lastname: Nakao
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D003131:Combined Modality Therapy; D036101:Cord Blood Stem Cell Transplantation; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D018365:Neoplasm, Residual; D036102:Peripheral Blood Stem Cell Transplantation; D010879:Piperazines / Q000008:administration & dosage*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000628:therapy*; D011743:Pyrimidines / Q000008:administration & dosage*; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate